At the DNC, ag leaders discuss need to invest in science

August 19, 2020
Today, we’re taking a look at what the ag industry (including BIO) said during the DNC yesterday, as well as how the VA is partnering to research COVID-19 and improve veterans’ access to clinical trials. Here are 730 words, 3 minutes, 40 seconds.
BIO

Today, we’re taking a look at what the ag industry (including BIO) said during the DNC yesterday, as well as how the VA is partnering to research COVID-19 and improve veterans’ access to clinical trials. Here are 730 words, 3 minutes, 40 seconds.

At the DNC, ag leaders discuss need to invest in science

As we mentioned yesterday, BIO’s Dr. Michelle McMurry-Heath and a few members spoke during the Leaders of American Agriculture virtual symposium at the Democratic National Convention. Here’s more on what she had to say. 

During every Democratic National Convention, Leaders of American Agriculture brings together the ag industry and policymakers to talk about key issues—and this year, the fun took place on Day 2 exclusively online. (Full disclosure: BIO sponsored the event.) 

One key theme was the importance of innovation in tackling big challenges like the economy and climate change. BIO President and CEO Dr. Michelle McMurry-Heath spoke on how to build resiliency in the agriculture value chain, which also featured Rep. TJ Cox (D-CA), Nikki Fried, Florida Commissioner of Agriculture and Consumer Services, Ben Thompson, Director, Montana Department of Agriculture, and bioeconomy innovators.

Dr. Michelle explained how science will help us solve our most pressing challenges—from obesity and diabetes, to food security and the need for sustainable infrastructure, to, of course, COVID-19.

She also touted the need for policies to support science and innovation—because “as bad as this pandemic has been, it pales in comparison to what awaits us if we don’t take bold and drastic action to combat climate change.” (She specifically mentioned One Health and the Growing Climate Solutions Act.)   

Two BIO members with some of these solutions also participated in the discussion's “welcome room,” including Sylvia Wulf, president and CEO of AquaBounty Technologies—a company that has pioneered more sustainable Atlantic salmon thanks to gene editing—and Pat Gruber, CEO of Gevo—a company that is developing clean-burning, plant-based aviation fuels.  

Dr. Michelle’s Diagnosis: Government and industry have an opportunity—and an obligation—to work together in the face of the threats to our economy, our families, and our way of life. We should believe the scientists’ warnings. We must change the narrative about the value of science in America to realize its transformative potential. Let’s invest in science and make sure all Americans can access its bounty. – BIO President and CEO Dr. Michelle McMurry-Heath

Agri-Pulse has more on what the ag industry said at the DNC yesterday.

 

More Agriculture and Environment News:

Farm Journal: Calyxt expands its gene-editing tech to more crops
“In 2020, the Calyxt high oleic soybeans were planted on 72,000 acres, which is double the acres planted in 2019.” 

The New York Times: Could owl and crocodilian tears lead to a cure for your dry eyes?
“By studying the numerous ways animals keep their eyes wet and healthy, scientists hope to help address human vision problems.”

 
Twitter
 
LinkedIn
 
Facebook
 

How the VA is helping fight COVID-19

We caught up with the National Association of Veterans’ Research and Education Foundations (NAVREF) to learn more about how the VA has been collaborating with the biotech industry and government agencies to accelerate COVID-19 research and improve veterans’ access to clinical trials.

VA Research has been working to improve collaboration with industry, particularly through the ACT for Veterans Initiative, which works to improve access to clinical trials among military veterans.

VA jumped in the COVID-19 fight, participating in a number of industry-sponsored studies for therapeutics including tocilizumab with Hoffman-La Roche and sarilumab with Regeneron, which are both used in arthritis care. 

In addition to participating in Operation Warp Speed and ACTIV, the VA also partnered with the Departments of Energy and Health & Human Services to coordinate and share health data, research, and expertise on COVID-19 therapeutics and vaccines

And VA’s Million Veteran Program (MVP) is collecting information about participants’ experiences, which could provide insight into the influence of race and ethnicity on disease susceptibility, severity, and outcomes since MVP’s population is around 20% African American and 7% Hispanic.

And it’s not just about COVID-19. VA is funding a phase 2 clinical trial exploring whether degarelix, a treatment used against prostate cancer, may improve clinical outcomes, as one example.

The bottom line? We need all kinds of collaboration to beat COVID-19. “Our industry is moving forward at an incredibly fast pace, and part of the reason is because of the unprecedented collaboration we’re seeing across the industry and with key government and nongovernmental partners,” as BIO’s Dr. Michelle McMurry-Heath recently said.

Learn more about VA collaborations to fight COVID-19.

 
Twitter
 
LinkedIn
 
Facebook
 
BIO Beltway Report
GoodDayBIO
 
 

President Trump’s Wednesday: Not much on the agenda other than an intelligence briefing. Meanwhile, ICYMI, Trump “canceled” scheduled trade talks with China

What’s Happening on Capitol Hill: On Day 2 of the virtual DNC, Joe Biden officially became the nominee and speakers included more than a dozen of “the next generation of party leaders” and Dr. Jill Biden. Tonight, VP nominee Sen. Kamala Harris and former President Barack Obama will headline.

 
 
Paragraph (normal) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus sample link.
 
Twitter
 
LinkedIn
 
Facebook